Cross-Sector entity
Lantern Pharma is most often covered alongside CIBC Private Wealth Group LLC, which appears in 3 of these 3 stories. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. We currently track 3 Cross-Sector stories that mention Lantern Pharma, all published on August 16, 2026.
3 verified stories tracked
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Lantern Pharma is most often covered alongside CIBC Private Wealth Group LLC, which appears in 3 of these 3 stories. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. We currently track 3 Cross-Sector stories that mention Lantern Pharma, all published on August 16, 2026. Each carries 2 original sources on average.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lantern Pharma. Shared-story counts are live from our verified record — not editorial picks.
Quarterly earnings release
Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
Weiss Ratings upgrade
Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
Wall Street Zen rating action
Research note on LTRN reported with conflicting direction across sources (upgrade to hold vs downgrade to sell).
Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Source: dailypolitical.com · themarketsdaily.com
